Fluicell AB Asset Resilience Ratio

Latest as of December 2025: 12.24%

Fluicell AB asset resilience ratio. Fluicell AB (FLUI) has an Asset Resilience Ratio of 12.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Fluicell AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr2.26 Million
≈ $243.43K USD Cash + Short-term Investments

Total Assets

Skr18.48 Million
≈ $1.99 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio of Fluicell AB (2016–2025)

Asset resilience ratio of Fluicell AB from 2016 to 2025. This chart shows how Fluicell AB's Asset Resilience Ratio has changed over time. Read FLUI total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Fluicell AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Fluicell AB assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr2.26 Million 12.24%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr2.26 Million 12.24%

Asset Resilience Insights

  • Moderate Liquidity: Fluicell AB has 12.24% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Fluicell AB Industry Peers by Asset Resilience Ratio

Compare Fluicell AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Fluicell AB Asset Resilience Ratio by Year (2016–2025)

Fluicell AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Fluicell AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 12.24% Skr2.26 Million
≈ $243.43K
Skr18.48 Million
≈ $1.99 Million
-50.18pp
2024-12-31 62.43% Skr15.92 Million
≈ $1.71 Million
Skr25.51 Million
≈ $2.75 Million
+32.85pp
2023-12-31 29.58% Skr2.76 Million
≈ $297.34K
Skr9.34 Million
≈ $1.01 Million
-47.41pp
2022-12-31 76.99% Skr24.46 Million
≈ $2.63 Million
Skr31.77 Million
≈ $3.42 Million
+0.29pp
2021-12-31 76.70% Skr20.69 Million
≈ $2.23 Million
Skr26.98 Million
≈ $2.90 Million
+0.98pp
2020-12-31 75.71% Skr18.80 Million
≈ $2.02 Million
Skr24.83 Million
≈ $2.67 Million
+33.40pp
2019-12-31 42.32% Skr8.44 Million
≈ $907.96K
Skr19.94 Million
≈ $2.15 Million
-43.27pp
2018-12-31 85.59% Skr22.23 Million
≈ $2.39 Million
Skr25.97 Million
≈ $2.80 Million
+17.69pp
2017-12-31 67.91% Skr7.83 Million
≈ $842.96K
Skr11.54 Million
≈ $1.24 Million
+28.30pp
2016-12-31 39.60% Skr1.10 Million
≈ $118.27K
Skr2.77 Million
≈ $298.63K
--
pp = percentage points

About Fluicell AB

ST:FLUI Sweden Biotechnology
Market Cap
$4.04 Million
Skr37.50 Million SEK
Market Cap Rank
#28939 Global
#643 in Sweden
Share Price
Skr27.30
Change (1 day)
+4.20%
52-Week Range
Skr7.95 - Skr57.20
All Time High
Skr188.78
About

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more